Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RNDB
2901
DELISTED
Randolph Bancorp, Inc. Common Stock
RNDB
| $499K | ﹤0.01% |
+28,300
| New | +$443K |
|
|
MESO
2902
Mesoblast
MESO
$2.18B
| $497K | ﹤0.01% |
33,734
-2,006
| -6% | -$25.6K |
|
|
CTB
2903
DELISTED
Cooper Tire & Rubber Co.
CTB
| $497K | ﹤0.01% |
17,300
-77,400
| -82% | -$2.19M |
|
|
FGNX
2904
FG Nexus Inc
FGNX
$40.2M
| $495K | ﹤0.01% |
717
-87
| -11% | -$52K |
|
2905
iShares MSCI Italy ETF
EWI
$1.08B
| $493K | ﹤0.01% |
+16,700
| New | +$481K |
|
2906
iShares Russell Top 200 Growth ETF
IWY
$16.7B
| $493K | ﹤0.01% |
+5,100
| New | +$466K |
|
|
CPE
2907
DELISTED
Callon Petroleum Company
CPE
| $493K | ﹤0.01% |
+10,199
| New | +$422K |
|
2908
Limoneira
LMNR
$251M
| $492K | ﹤0.01% |
25,600
-34,600
| -57% | -$661K |
|
2909
VSE Corp
VSEC
$6.81B
| $491K | ﹤0.01% |
12,900
+1,500
| +13% | +$55.8K |
|
|
ALPN
2910
DELISTED
Alpine Immune Sciences Inc
ALPN
| $491K | ﹤0.01% |
127,810
+15,449
| +14% | +$48.2K |
|
2911
BioLife Solutions
BLFS
$1.72B
| $490K | ﹤0.01% |
30,254
+14,954
| +98% | +$243K |
|
2912
Citizens Community Bancorp
CZWI
$200M
| $489K | ﹤0.01% |
40,000
+15,200
| +61% | +$176K |
|
2913
Virtus Investment Partners
VRTS
$1.12B
| $487K | ﹤0.01% |
4,000
-17,429
| -81% | -$1.94M |
|
|
SISI
2914
DELISTED
Shineco
SISI
| $486K | ﹤0.01% |
7
| – | – |
|
2915
Sypris Solutions
SYPR
$46.8M
| $486K | ﹤0.01% |
623,497
+14,800
| +2% | +$13.5K |
|
|
AMBR
2916
Amber International Holding Ltd
AMBR
$124M
| $486K | ﹤0.01% |
+15,107
| New | +$480K |
|
|
HBP
2917
DELISTED
Huttig Building Products, Inc.
HBP
| $484K | ﹤0.01% |
314,206
-2,900
| -0.9% | -$5.67K |
|
|
ICON
2918
DELISTED
Iconix Brand Group, Inc.
ICON
| $481K | ﹤0.01% |
356,378
+50,300
| +16% | +$82.2K |
|
2919
Bio-Rad Laboratories Class B
BIO.B
| $480K | ﹤0.01% |
1,300
+100
| +8% | +$35.3K |
|
|
VXRT
2920
DELISTED
Vaxart
VXRT
| $480K | ﹤0.01% |
1,369,774
+403,821
| +42% | +$134K |
|
2921
Icahn Enterprises
IEP
$5.33B
| $479K | ﹤0.01% |
7,794
-66
| -0.8% | -$4.27K |
|
|
XENT
2922
DELISTED
Intersect ENT, Inc
XENT
| $478K | ﹤0.01% |
+19,200
| New | +$389K |
|
2923
Live Oak Bancshares
LOB
$1.98B
| $477K | ﹤0.01% |
25,100
+11,700
| +87% | +$216K |
|
2924
Invesco S&P MidCap Momentum ETF
XMMO
$7.61B
| $477K | ﹤0.01% |
7,800
+1,400
| +22% | +$83.1K |
|
2925
AllianceBernstein
AB
$3.4B
| $474K | ﹤0.01% |
15,673
-591
| -4% | -$17.2K |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.